Connected health company Withings has partnered with period tracking app Clue to integrate health data from the Withings ScanWatch 2 with Clue Plus. The collaboration provides women with a comprehensive view of how hormonal fluctuations impact their overall health.
The partnership launches with a bundle offering the ScanWatch 2 plus a one-year Clue Plus subscription for $379.95, representing a 75% discount on the annual Clue Plus membership.
The ScanWatch 2 monitors 35 health parameters including sleep quality, stress regulation, cardiovascular health through medical-grade ECG, and core body temperature via heat-flux sensors. The device features a 35-day battery life.
“Partnering with Withings was a natural step for us. Our two brands have a strong commitment to women’s health empowerment,” said Rhiannon White, CEO of Clue. “We are aligned on science-based health tracking, with strict data privacy and compliance with CE and FDA medical-grade standards.”
The integration addresses research gaps in women’s health, which has historically been viewed through male physiology. The combined platform supports women across cycle tracking, pregnancy/conception, and perimenopause by providing comprehensive views of how hormonal phases affect sleep, stress, activity levels, and temperature.
“We are excited to partner with Clue to provide women worldwide a better view of their health—combining Clue’s powerful cycle insights with ScanWatch’s 24/7 health tracking,” said Aline Criton, Chief Medical Officer at Withings.
The ScanWatch 2’s TempTech 24/7 technology distinguishes core body temperature from environmental factors, enabling continuous monitoring essential for cycle tracking. The device includes medical-grade ECG capabilities for detecting conditions like atrial fibrillation, which becomes more prevalent after menopause.
Clue Plus members receive a 10% discount on Withings products, while Withings purchases include a free one-month Withings+ membership.
